NCT07587710尚未招募1 期
A Study Investigating the Pharmacokinetic Properties, Safety and Tolerability of NNC0487-0111 in Participants With Various Degrees of Hepatic Impairment and Participants With Normal Hepatic Function
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 35
- 试验地点
- 2
研究概览
简要总结
The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people with normal liver function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female (sex at birth).
- •Age 18-80 years (both inclusive) at the time of signing informed consent.
- •Participants with stable hepatic impairment classified as Child-Pugh grade A, B or C as assessed by the investigator. Stable hepatic impairment is defined as no clinically significant change in disease status, as judged by the investigator.
排除标准
- •Known or suspected hypersensitivity to study intervention(s) or related products.
- •Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 DiabetesType 2 DiabetesHealthy VolunteerNCT07270731Novo Nordisk A/S60
招募中
1 期
A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DMHealthy VolunteersDiabetes Mellitus, Type 2NCT07570992Novo Nordisk A/S58
已完成
2 期
UBT251 注射液在超重 / 肥胖患者中的Ⅱ期研究超重、肥胖CTR20250288联邦生物科技（珠海横琴）有限公司
Unknown
2 期
评估 UBT251 注射液在超重 / 肥胖患者中有效性和安全性的随机、双盲、平行、安慰剂对照Ⅱ期研究ChiCTR2500113817联邦生物科技（珠海横琴）有限公司200
招募中
Phase 3 4
Clinical trial on body fat loss in overweight subjectsCTRI/2025/01/079489Daehan chemtech co., Ltd.150